KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Liabilities and Shareholders Equity (2016 - 2026)

TherapeuticsMD filings provide 17 years of Liabilities and Shareholders Equity readings, the most recent being $37.6 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 1.71% to $37.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $152.4 million, a 2.76% decrease, with the full-year FY2025 number at $37.7 million, down 3.0% from a year prior.
  • Liabilities and Shareholders Equity hit $37.6 million in Q1 2026 for TherapeuticsMD, roughly flat from $37.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $146.2 million in Q2 2022 to a low of $37.6 million in Q1 2026.
  • Median Liabilities and Shareholders Equity over the past 5 years was $42.1 million (2024), compared with a mean of $62.5 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 63.28% in 2023 and later decreased 1.71% in 2026.
  • TherapeuticsMD's Liabilities and Shareholders Equity stood at $90.5 million in 2022, then crashed by 52.12% to $43.3 million in 2023, then fell by 10.36% to $38.8 million in 2024, then fell by 3.0% to $37.7 million in 2025, then dropped by 0.2% to $37.6 million in 2026.
  • The last three reported values for Liabilities and Shareholders Equity were $37.6 million (Q1 2026), $37.7 million (Q4 2025), and $38.7 million (Q3 2025) per Business Quant data.